A Case of Severe Chronic Progressive Axonal Polyradiculoneuropathy Temporally Associated With Anti-CV2/CRMP5 Antibodies

  title={A Case of Severe Chronic Progressive Axonal Polyradiculoneuropathy Temporally Associated With Anti-CV2/CRMP5 Antibodies},
  author={Yousef Hannawi and Corey E. Goldsmith and Joseph Shimon Kass and Adriana Olar and Eroboghene E Ubogu and Yogeshwar V. Kalkonde},
  journal={Journal of Clinical Neuromuscular Disease},
Objectives: The involvement of the peripheral nervous system by anti-CV2/CRMP5 paraneoplastic antibodies is typically encountered as a mixed sensorimotor polyneuropathy. We report a fatal case of severe chronic progressive axonal polyradiculoneuropathy in association with this antibody. Methods: Review of the patient's chart, nerve conduction/electromyographic studies, and nerve biopsy. Results: A 51-year-old man presented with a progressive quadriparesis over a 4-month period. Extensive… 

Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review

The case of a patient with CRMP5 antibody-positive paraneoplastic neurological syndrome (PNS) that is associated with autonomic dysfunction (presenting most remarkably as CIPO) is reported.

Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour

This case is unusual for the strikingly unilateral neuroimaging abnormalities, which led to an initial misdiagnosis, and the spontaneous symptomatic improvement without treatment, which underlines the importance in clinical reasoning of avoiding the cognitive errors of premature closure and anchoring.

Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications

Observations provide proof of concept that identifying the target antigens in tissue-specific antibody-mediated autoimmune diseases is important, not only to understand their underlying pathogenic mechanisms, but also to correctly diagnose and treat affected patients.

Abnormal movements in critical care patients with brain injury: a diagnostic approach

A practical paradigm that can be applied at the bedside for diagnosing abnormal movements in the ICU is proposed, which integrates the frequency and type of each movement with the availability of ancillary diagnostic tests and the specific etiology of brain injury.



Paraneoplastic neurological syndromes.

The number of antibodies relevant to PNS is now expanded to those against surface antigens, which do not confirm the paraneoplastic origin of the syndrome but predict a better response to immunotherapy.

Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma

A 60 year-old woman with locally advanced squamous cell carcinoma of the tongue who developed a subacute cerebellar syndrome associated with the presence of anti-CV2/CRMP5 antibodies in the cerebrospinal fluid, after achieving complete remission of the primary tumor and the involved cervical lymph nodes by chemoradiation is reported.

Paraneoplastic syndromes of the peripheral nerves

Of this group of disorders, paraneoplastic sensory neuronopathies are the most frequent; many of these patients have anti-Hu antibodies and small-cell lung cancer.

Cerebrospinal fluid study in paraneoplastic syndromes

CSF inflammation is a common finding in paraneoplastic neurological syndromes patients and can be a helpful tool for diagnosis, especially if this analysis is done within 3 months after neurological onset.

Paraneoplastic anti‐CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy

This work has compared the clinical, electrophysiological, and pathological characteristics of the peripheral neuropathy in 9 patients with anti‐CV2 antibodies (3 of whom also had anti‐Hu antibodies) and 12 patients with only anti‐ Hu antibodies, which indicated subacute sensory neuronopathy.

Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.

The combination of symptoms, MRI findings and paraneoplastic antibodies established the diagnosis of PLE in 78% of the patients, and treatment of the tumour appeared to have more effect on the neurological outcome than the use of immune modulation.

[Paraneoplastic peripheral neuropathies].

Recent data suggest that gangliosides may be the target of the immune process in neuropathies associated with melanoma, and the neuropathy improves with treatment of the tumor.

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies

It is demonstrated that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and thetype of tumour.

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone

This study suggests that vigorous immunosuppressive treatment is not useful in severely disabled PNS patients with antineuronal Abs and in a minority of patients who are not severely disabled at the onset of treatment, a transient stabilisation is possible and deserves further evaluation.

Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.

The detection of anti-CV2 antibodies in patients with neurological disorders should be considered as an indication of the presence of an occult cancer.